当前位置:首页 > 文献互助 > 互助详情

Progress in the Treatment of Refractory Myasthenia Gravis复制

用户wxb8loTerxGI 1个月前 59 10 已完结

1. 系统已在2026-03-16 11:33:06对应助文件进行删除

2. 如有需要请重新发布求助信息

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI:复制

文献链接:复制

其他信息:

D Liu, J Mao, J Song, M Wang
Revista de Neurología, 2026
imrpress.com
Myasthenia gravis (MG) is an autoantibody-mediated, cellular immune-dependent and complement system-involved autoimmune disorder characterized by acquired neuromuscular junction transmission dysfunction driven by genetic and environmental factors. Approximately 10% therapies such as cholinesterase inhibitors, glucocorticoids, and immunosuppressants, resulting in the development of refractory MG (RMG). The current emergence of new therapeutic strategies such as targeted biologics (eg, complement …

互助时间线

2026-03-09 13:25:15 [完结求助]

楼主确认了jodie0105应助的文件是正确的, 求助状态变成 已完结

2026-03-09 11:33:06 [上传文件]

jodie0105上传了文件(pdf 6.17 MB), 求助状态变成 待确认

2026-03-06 19:48:41 [发起求助]

最新发布的求助